FinTechFunding

Immutep: Shares positive data from phase 2b AIPAC trial

Immutep Shares positive data from phase 2b AIPAC trial

  • Immutep (IMM) sees a significant increase in innate and adaptive immune response biomarkers in its phase IIb AIPAC trial
  • The trial evaluated efti combined with paclitaxel chemotherapy compared to a placebo group in 227 patients with HER2-negative/HR-positive metastatic breast cancer
  • IMM says the higher immune response in efti patients compared to placebo patients confirms efti is activating the immune system and improving overall survival
  • The company is a globally active biotechnology company that is a leader in developing LAG-3 related immunotherapeutic products
  • The company is trading 7.58 per cent higher at 35.5 cents
Previous article
Intigriti: Raises Over €21.13M in Series B Funding
Next article
Elixir Energy: Completes Tim-2 well in Mongolia
Steve Sam
Steve Sam
Steve Sam is a financial reporter, analyst, and commentator with a strong focus on banking technology, digital payments, and the future of financial services.

You May Also Like

FinTech

eToro Strengthens Crypto Portfolio with Zengo Acquisition

Deal expands eToro's offerings in the cryptocurrency sector.Highlights: eToro is acquiring crypto wallet Zengo to expand its services.The...
FinTech

Revolut Launches Platform to Streamline Overseas Talent Hiring

Revolut's new service aims to simplify global recruitment for businesses.Highlights: Revolut launches a platform for hiring overseas talent.The...
FinTech

Revolut Strengthens Business Recruitment Platform in New Markets

The fintech giant expands its offerings targeting recruitment needs globally.Highlights: Revolut enhances its platform for business recruitment.The expansion...
FinTech

UniCredit Selects Slate to Strengthen Retail Investment Services

The partnership aims to enhance digital investment options for customers.Highlights: UniCredit partners with Slate for enhanced retail investment...